Huimin M. Liu

154 Anshan Road
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

The Clinical Research of the Chronic Cough After COVID-19 Infection.

The Clinical Research of the Chronic Cough After COVID-19 Infection.

Journal: Journal of clinical medicine

Published: January 17, 2026

Long-term outcomes of vindesine or vincristine substitutions for vinblastine in classical Hodgkin lymphoma.

Long-term outcomes of vindesine or vincristine substitutions for vinblastine in classical Hodgkin lymphoma.

Journal: Chinese medical journal

Published: January 12, 2026

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal

Published: May 06, 2025

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal

Published: May 06, 2025

Rituximab combined with intensive immunochemotherapy for sporadic adult Burkitt lymphoma: efficacy and prognosis analyse

Rituximab combined with intensive immunochemotherapy for sporadic adult Burkitt lymphoma: efficacy and prognosis analyse

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 26, 2025

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.

Journal: Cancer biology & medicine

Published: March 12, 2025

Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker.

Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker.

Journal: International journal of chronic obstructive pulmonary disease

Published: February 21, 2025

Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study.

Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 28, 2024

Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review

Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 16, 2024

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.

Journal: Journal for immunotherapy of cancer

Published: March 25, 2024

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.

Journal: Journal for immunotherapy of cancer

Published: January 27, 2024

Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.

Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.

Journal: Cancer medicine

Published: November 06, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026